AK HB292

Requires health care insurers in Alaska to cover the prophylaxis, diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), including antimicrobials, medication, behavioral therapies, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy

Prohibits insurers from denying or delaying coverage based on prior treatment history, a different diagnostic name (such as autoimmune encephalopathy), or the enrollee's age, and bars denial of out-of-state treatment if the service is unavailable in Alaska

Prohibits insurers from requiring a trial of symptom-only therapies before authorizing immunomodulating treatments, and requires that any coverage limitations be consistent with best-practice treatment guidelines developed by a research consortium

Mandates that coverage for PANDAS/PANS not be more restrictive than coverage for any other illness or condition with respect to deductibles, copayments, coinsurance, and benefit limits

Takes effect January 1, 2027